26 recruiting, 11 active not recruiting, 7 completed, 2 suspended. 51 Phase 2, 12 Phase 1, 3 Phase 3.
Follow Ruxience: new trials by email Literature Review of Ruxience trials Research Report on Ruxience
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Recruiting | University of Utah | 23 | 2026-11-05 | 2026-11-09 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Recruiting | AIDS Malignancy Consortium | 43 | 2026-09-16 | 2026-11-17 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study Acalabrutinib, Rituximab, Glofitamab - Phase 2 Study, MCL | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-04-01 | 2026-11-17 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Venetoclax, Rituximab - Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 33 | 2026-02-11 | 2026-03-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-10-30 |
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Not yet recruiting | Fox Chase Cancer Center | 24 | 2025-06-01 | 2025-01-06 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
Showing 20 of 51. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (9) · Burkitt Lymphoma (8) · Lymphoma (7) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Mantle-Cell (7) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Lymphoma, Follicular (3) · Hodgkin Disease (2) · Leukemia (2) · Lymphoma, Non-Hodgkin (2) · Anemia, Sickle Cell (1) · Diabetes Mellitus, Type 1 (1) · Disease (1)
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (6) · University of Washington (6) · City of Hope Medical Center (5) · Academic and Community Cancer Research United (3) · Mayo Clinic (2) · University of California, Davis (2) · AIDS Malignancy Consortium (1) · BioInvent International AB (1) · Children's Oncology Group (1) · Christine Ryan (1) · Columbia University (1) · Fox Chase Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Gottfried von Keudell, MD PhD (1)
United States (50) · Canada (2) · Australia (1) · Brazil (1) · Germany (1) · Poland (1) · Spain (1) · Sweden (1)
Geoffrey Shouse (2) · Grzegorz S Nowakowski (2) · Joseph M Tuscano (2) · Mengyang Di, MD, PhD (2) · Alain Mina, M.D. (1) · Alexey V Danilov (1) · Ariela Noy (1) · Birte Wistinghausen (1) · Bouthaina S Dabaja (1) · Catherine S Diefenbach (1) · Christine Ryan, MD (1) · Claire Tiger, MD, PhD (1) · Daniel Moore, MD (1) · Daniel O Persky (1) · Elias Jabbour, MD (1)
PMID 28945884, PMID 29531316, PMID 29785709, PMID 30530801, PMID 30575311, PMID 34555839, PMID 34634256, PMID 34686472, PMID 34797699, PMID 35074072, PMID 35787017, PMID 36521030, PMID 38163318, PMID 39352751, PMID 39735417, PMID 40331908, PMID 40550489, PMID 40802906, PMID 42305039, PMID 42660130
P30CA033572 (5), U10CA180821 (4), P30CA015083 (3), U10CA180888 (3), P30CA093373 (2), U10CA031946 (2), P30CA060553 (1), P50CA097274 (1), U10CA021115 (1), U10CA032102 (1), U10CA180820 (1), U10CA180886 (1), U24CA196172 (1), UC4DK117009 (1), UM1CA121947 (1)